Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACRX Stock Forecast 2026-2027
$0.72
Current Price
$12.24M
Market Cap
Buy 3
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to ACRX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
ACRX Price Momentum
0.0%
1 Week Change
-19.1%
1 Month Change
+46.9%
1 Year Change
-36.8%
Year-to-Date Change
-54.0%
From 52W High of $1.57
+90.1%
From 52W Low of $0.38
📊 TOP ANALYST CALLS
Did ACRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AcelRx is one of their latest high-conviction picks.
Latest ACRX Stock Price Targets & Analyst Predictions
ACRX has shown a year-to-date change of -36.8% and a 1-year change of 46.9%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ACRX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACRX Analyst Ratings
3
Buy
2
Hold
0
Sell
ACRX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.72
Latest ACRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 22, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 7, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Oct 2, 2023 | Alliance Global Partners | James Molloy | Buy | Initiates | $4.25 |
| Sep 25, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $5.00 |
| Aug 18, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Upgrade | $8.00 |
| Mar 14, 2022 | HC Wainwright & Co. | Ed Arce | Neutral | Downgrade | $N/A |
| Aug 17, 2021 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $5.00 |
| Aug 13, 2020 | Credit Suisse | Underperform | Maintains | $0.84 | |
| Jul 20, 2020 | Credit Suisse | Evan Seigerman | Underperform | Downgrade | $0.69 |
| Mar 17, 2020 | H.C. Wainwright | Buy | Maintains | $N/A | |
| Mar 17, 2020 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $7.00 |
| Nov 11, 2019 | Credit Suisse | Neutral | Downgrade | $2.00 | |
| Apr 24, 2019 | B. Riley FBR | Buy | Initiates | $N/A | |
| Feb 15, 2019 | Credit Suisse | Outperform | Initiates | $N/A | |
| Oct 23, 2018 | B. Riley FBR | Buy | Initiates | $N/A | |
| Oct 15, 2018 | Jefferies | Buy | Upgrade | $N/A | |
| Oct 10, 2018 | Ladenburg Thalmann | Buy | Reiterates | $10.00 | |
| Aug 16, 2018 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Jul 13, 2018 | Oppenheimer | Perform | Initiates | $N/A | |
| Jun 12, 2018 | Cantor Fitzgerald | Overweight | Initiates | $N/A |
AcelRx Pharmaceuticals Inc (ACRX) Competitors
The following stocks are similar to AcelRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AcelRx Pharmaceuticals Inc (ACRX) Financial Data
Valuation Metrics
Market Cap
$12.24M
Enterprise Value
$0
P/E Ratio
0.1x
PEG Ratio
N/A
Price/Sales
18.8x
Growth & Margins
Revenue Growth (YoY)
+140.2%
Gross Margin
N/A
Operating Margin
-1,559.6%
Net Margin
N/A
EPS Growth
+11.5%
Financial Health
Cash/Price Ratio
N/A
Current Ratio
2.6x
Debt/Equity
0.0x
ROE
-130.4%
ROA
-90.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
AcelRx Pharmaceuticals Inc (ACRX) Business Model
About AcelRx Pharmaceuticals Inc
What They Do
Develops therapies for acute pain management.
Business Model
AcelRx Pharmaceuticals focuses on specialty pharmaceuticals, primarily developing and commercializing products for managing acute pain. The company's revenue is generated through the sale of its lead products, such as DSUVIA and DZUVEO, along with ongoing clinical trials for additional therapies aimed at various pain management and treatment scenarios.
Additional Information
The company is engaged in several clinical trials, including ARX-02 for cancer breakthrough pain and ARX-03 for procedural anxiety, indicating a pipeline aimed at expanding its product offerings. AcelRx Pharmaceuticals was founded in 2005 and is based in Hayward, California.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Employees
19
CEO
Mr. Vincent J. Angotti
Country
United States
IPO Year
2011
Website
www.acelrx.comAcelRx Pharmaceuticals Inc (ACRX) Latest News & Analysis
Latest News
Quick Summary
AcelRx Pharmaceuticals is rebranding as Talphera, Inc. and will trade on Nasdaq under the symbol "TLPH" starting January 10, 2024.
Why It Matters
The rebranding to Talphera and new Nasdaq symbol "TLPH" signify a strategic pivot, potentially enhancing market perception and attracting investor interest in innovative therapies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
AcelRx Pharmaceuticals announced a study on U.S. physician anticoagulation use during CRRT for acute kidney injury, highlighting challenges with current anticoagulants heparin and citrate.
Why It Matters
Increased CRRT use indicates a growing market for related therapies, potentially benefiting AcelRx Pharmaceuticals as it develops anticoagulants, signaling future revenue opportunities.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
AcelRx Pharmaceuticals will host its Q3 2023 earnings conference call on November 8, 2023, at 4:30 PM ET, featuring key executives including the CEO and CFO.
Why It Matters
AcelRx's Q3 2023 earnings call could reveal key financial metrics and strategic developments, impacting stock performance and investor sentiment on future growth prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Niyad received FDA IDE approval in Q3 2023 and plans a registrational study this quarter, with topline data expected mid-2024. Cash and investments total $13.4 million. Financing of $26.3 million closed in July.
Why It Matters
FDA approval of the Niyad device and upcoming registrational study could drive investor interest, potentially increasing the company's valuation and market confidence. Strong cash reserves support growth plans.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A webcast on December 6, 2023, at 11:00 a.m. ET will feature KOLs discussing anticoagulant usage in dialysis and the Niyad study protocol for the NEPHRO Study.
Why It Matters
The webcast on anticoagulants in dialysis and the Niyad study could signal advancements or regulatory changes, impacting related biotech stocks and market strategies.
Source: PRNewsWire
Market Sentiment:
Neutral
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
2 years ago
Quick Summary
AcelRx Pharmaceuticals (Nasdaq: ACRX) will release its Q3 2023 financial results on November 8, 2023, after market close, followed by a live webcast at 4:30 p.m.
Why It Matters
AcelRx's upcoming financial results could impact stock performance, offering insights into its growth and operational health, crucial for investment decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ACRX Stock
What is AcelRx Pharmaceuticals Inc's (ACRX) stock forecast for 2026?
Analyst forecasts for AcelRx Pharmaceuticals Inc (ACRX) are not currently available. The stock is trading at $0.72.
Is ACRX stock a good investment in 2026?
According to current analyst ratings, ACRX has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACRX stock?
Price predictions from Wall Street analysts for ACRX are not currently available. The stock is trading at $0.72.
What is AcelRx Pharmaceuticals Inc's business model?
AcelRx Pharmaceuticals focuses on specialty pharmaceuticals, primarily developing and commercializing products for managing acute pain. The company's revenue is generated through the sale of its lead products, such as DSUVIA and DZUVEO, along with ongoing clinical trials for additional therapies aimed at various pain management and treatment scenarios.
What is the highest forecasted price for ACRX AcelRx Pharmaceuticals Inc?
Price targets from Wall Street analysts for ACRX are not currently available. The stock is trading at $0.72.
What is the lowest forecasted price for ACRX AcelRx Pharmaceuticals Inc?
Price targets from Wall Street analysts for ACRX are not currently available. The stock is trading at $0.72.
What is the overall ACRX consensus from analysts for AcelRx Pharmaceuticals Inc?
The overall analyst consensus for ACRX is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell.
How accurate are ACRX stock price projections?
Stock price projections, including those for AcelRx Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 12:12 AM UTC